Trials / Completed
CompletedNCT00325390
Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation
Double-Blind Parallel Comparison Study of SR25990C Versus Standard Therapy in Japan(Ticlopidine) in Patients With Acute Coronary Syndrome Without ST-Segment Elevation Who Are Planned for Percutaneous Coronary Intervention
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 800 (planned)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the efficasy and safety of SR25990C(loading dose:300mg, maintenance dose:75mg/day) in comparison with the standard Japanese treatment(ticlopidine) in patients with acute coronary syndrome without ST-segment elevation and planned for percutaneous coronary intervention(including stenting).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | clopidogrel (SR25990C) |
Timeline
- Start date
- 2004-07-01
- First posted
- 2006-05-12
- Last updated
- 2009-03-25
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00325390. Inclusion in this directory is not an endorsement.